US.RMD · ResMed

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.7764823754440293,
        "turnoverUsdM": 181.39262262,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.RMD",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 207.3868,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2.5,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 5.6,
      "take_profit_price": 232.515,
      "target_multiplier": 1.9,
      "technical_strength": 1.68,
      "take_profit_percent": 5.9
    },
    "positionPoints": 1.4,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.552964750888059,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 46,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 42,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 4
  },
  "market": {
    "ma20": 229.1715,
    "ma50": 216.6216,
    "close": 219.58,
    "prevClose": 219.95,
    "avgVolume20": 1345059,
    "volumeRatio": 0.61,
    "changePercent": -0.17
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 4,
    "details": {
      "ret_5d": -0.04890197946896513,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 4,
      "vcp_bonus": 0,
      "vol_ratio": 0.6012686420507893,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.9641789207612202,
      "volat_points": 0,
      "day_range_pct": 0.024833819109208385,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 4,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 46,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.3,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 86,
        "contribution": 4.3
      },
      {
        "raw": 6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 4.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 30.67,
        "contribution": 4.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 66,
        "contribution": 6.6
      },
      {
        "raw": 15.5,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 51.67,
        "contribution": 15.5
      },
      {
        "raw": 3,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 30,
        "contribution": 3
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 42,
    "details": [
      "基本面分析總分: 4.3/5分",
      "資金流分析總分: 6/20分",
      "市場環境分析總分: 4.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.6/10分",
      "技術信號分析總分: 15.5/30分",
      "情緒分析: 3/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4.3,
      "資金流": 6,
      "市場環境": 4.6,
      "情緒分析": 3,
      "技術信號": 15.5,
      "風險管理": 6.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 6,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.4,
          "epsPoints": 0,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.75,
          "turnoverUsdM": 181.39262262,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 1.6,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.RMD",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 716.52749955,
                "ma50": 710.6121986999997,
                "name": "QQQ",
                "close": 708.69,
                "points": 0.4
              },
              "spy": {
                "ma20": 767.5584954500001,
                "ma50": 758.2458016200002,
                "name": "SPY",
                "close": 757.83002,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.7764823754440293,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 3,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 6,
              "negativeHits": 0,
              "positiveHits": 1,
              "sentimentScoreRaw": 0.4
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141396717,
                "url": "https://finnhub.io/api/news?id=afa84d7093fb6b05f41f002fc7c37c81899c605853691415deeac8190bcac69f",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "RMD",
                "summary": "ResMed (RMD) earns a high ChartMill Dividend Rating with a sustainable 1.25% yield, 22.95% payout ratio, and top-tier profitability and health scores.",
                "category": "company",
                "datetime": 1788429735,
                "headline": "ResMed (NYSE:RMD): A Quality Dividend Play Built on Sustainable Payouts"
              },
              {
                "id": 141259118,
                "url": "https://finnhub.io/api/news?id=a4f03eaf20b67dad07870e03380efd8a674caf30e00758efdf24378602e63067",
                "image": "",
                "source": "Fintel",
                "related": "RMD",
                "summary": "",
                "category": "company",
                "datetime": 1787196494,
                "headline": "Rothschild & Co Initiates Coverage of ResMed (RMD) with Neutral Recommendation"
              },
              {
                "id": 141275169,
                "url": "https://finnhub.io/api/news?id=7780e3047802952d0dfd4c4557447523f9ac589aafe27fbd60e4ba7e88234d2e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "On August 6, ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 results capping a year of double-digit growth. Quarterly revenue rose 9% to $1.5 billion, and non-GAAP earnings per share jumped 16% to $2.95. For the full fiscal year, which closed June 30, 2026, revenue grew 10%, and free cash flow topped $1.6 billion. The company also […]",
                "category": "company",
                "datetime": 1786998538,
                "headline": "ResMed’s (RMD) Sleep Business Booms Even As One Product Stumbles"
              },
              {
                "id": 141275171,
                "url": "https://finnhub.io/api/news?id=b5f32ab2e3e87e8f0847e4ace796197049f06e41e2447e0e089e91e61cf5fb74",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Farrell discusses strategic divestitures, capital returns, and AI digital health expansion.",
                "category": "company",
                "datetime": 1786724008,
                "headline": "ResMed (RMD) Q4 2026 Earnings Call Transcript"
              },
              {
                "id": 141202371,
                "url": "https://finnhub.io/api/news?id=a14265c9592c375e48e5eb528b975618d736e006f258f344b092ca3a052a5fc6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "ResMed stock has lagged over the past year, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples currently point to the shares trading at a discount to what the underlying cash flows may justify. ResMed has returned 26.3% over the past 3 years, which suggests that longer term holders have still seen gains despite the recent share price weakness. Recent pressure around a softer outlook and suspended ventilator sales can weigh on sentiment, while...",
                "category": "company",
                "datetime": 1786529545,
                "headline": "ResMed (RMD) Stock May Be 31% Undervalued After Soft FY27 Outlook"
              },
              {
                "id": 141202372,
                "url": "https://finnhub.io/api/news?id=ac834b7859cf4b846702996dda6c6e37f63e3abb547173b38d11e3b8ddae9292",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "In early August 2026, ResMed reported past fourth-quarter and full-year results showing higher sales and earnings, announced a 10% increase in its quarterly US$0.66 dividend, and confirmed completion of a long-running US$1.40 billions share buyback program. At the same time, management issued a softer fiscal 2027 outlook tied to suspended ventilator sales after an FDA Class 1 recall and ongoing cost pressures, sharpening investor focus on how resilient ResMed’s broader sleep-health and...",
                "category": "company",
                "datetime": 1786502030,
                "headline": "Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)?"
              }
            ],
            "raw_source": [
              {
                "id": 142058499,
                "url": "https://finnhub.io/api/news?id=e5fd87e803a79f42296ca95c952990912e964e36f801a4e5194d052345279d6d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/490998370/image_490998370.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "RMD",
                "summary": "ResMed has been de-rated from 30x to under 21x earnings despite 17% EPS growth, driven by narrative rather than fundamentals. See why RMD stock is a Buy.",
                "category": "company",
                "datetime": 1789024713,
                "headline": "ResMed: A Significant Upside Despite The Perceived Risk"
              },
              {
                "id": 141396717,
                "url": "https://finnhub.io/api/news?id=afa84d7093fb6b05f41f002fc7c37c81899c605853691415deeac8190bcac69f",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "RMD",
                "summary": "ResMed (RMD) earns a high ChartMill Dividend Rating with a sustainable 1.25% yield, 22.95% payout ratio, and top-tier profitability and health scores.",
                "category": "company",
                "datetime": 1788429735,
                "headline": "ResMed (NYSE:RMD): A Quality Dividend Play Built on Sustainable Payouts"
              },
              {
                "id": 141380550,
                "url": "https://finnhub.io/api/news?id=498393ba25e6c8fc9567b7b72a434e5741e8968c7096551d854927c27fa4383e",
                "image": "",
                "source": "Benzinga",
                "related": "RMD",
                "summary": "https://www.sec.gov/ix?doc=/Archives/edgar/data/0000943819/000119312526378487/d530283d8k.htm",
                "category": "company",
                "datetime": 1788280610,
                "headline": "ResMed Announces $450M Accelerated Share Repurchase Agreement With Citibank"
              },
              {
                "id": 141364474,
                "url": "https://finnhub.io/api/news?id=093179f12cc67693a19d2964c703d4644155711d6cf191d972a7300d9cf422c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "SEATTLE, September 01, 2026--Frazier Healthcare Partners (\"Frazier\"), a private equity firm focused exclusively on the healthcare industry, today announced the closing of its acquisition of MatrixCare (the \"Company\") from Resmed (NYSE & ASX: RMD).",
                "category": "company",
                "datetime": 1788269400,
                "headline": "Frazier Healthcare Partners Completes Acquisition of MatrixCare, Appoints Jonathan Lujan as Chief Executive Officer"
              },
              {
                "id": 141363416,
                "url": "https://finnhub.io/api/news?id=718c8b8586d56fb862b6846353f862595cff6b57180c0a309eda06b9ed4ca0fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.",
                "category": "company",
                "datetime": 1788265820,
                "headline": "2 Profitable Stocks Worth Investigating and 1 We Turn Down"
              },
              {
                "id": 141355224,
                "url": "https://finnhub.io/api/news?id=e8f0f49c3f8196b5710c2992901af7dab6a8b2bcefff86e5784d7c8cd6bf6607",
                "image": "",
                "source": "Benzinga",
                "related": "RMD",
                "summary": "Keybanc  analyst Brett Fishbin   maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $255 to $267.",
                "category": "company",
                "datetime": 1788164674,
                "headline": "Keybanc Maintains Overweight on ResMed, Raises Price Target to $267"
              },
              {
                "id": 141364471,
                "url": "https://finnhub.io/api/news?id=4775470059e18d6d96790db70a287693d6a3c8acbaea6860da9bbe1043add5e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 24th Annual Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026. Resmed’s webcast presentation will begin at approximately 10:00 a.m. (Eastern Time). More information about this event, including access to the live, audio-only webcast, may be accessed by visit",
                "category": "company",
                "datetime": 1787864700,
                "headline": "Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference"
              },
              {
                "id": 141362265,
                "url": "https://finnhub.io/api/news?id=4e4ec3d3366dc3946dec493db25b464b0b750bfd43f33a0f1ce6f114d110ec9c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
                "category": "company",
                "datetime": 1787850067,
                "headline": "2 S&P 500 Stocks with Promising Prospects and 1 We Ignore"
              },
              {
                "id": 141364472,
                "url": "https://finnhub.io/api/news?id=33c3080eb4b443573f0722d7ed35b805bbf559c0bc9c7d3ebc54e83d97a05e27",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Although ResMed has underperformed the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.",
                "category": "company",
                "datetime": 1787673103,
                "headline": "ResMed Stock: Analyst Estimates & Ratings"
              },
              {
                "id": 141364473,
                "url": "https://finnhub.io/api/news?id=6dea5dd1acee94edb0bb495f6b16ae53592772f006de8f37032a3060ad387ea1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Reddick, a 13-time NASCAR Cup Series winner and 2026 Daytona 500 Champion, shares how prioritizing sleep health is an important part of his recovery and performance routineSAN DIEGO, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced a new collaboration with 23XI Racing and their NASCAR Cup Series driver Tyler Reddick to encourage more people to recognize the signs of sl",
                "category": "company",
                "datetime": 1787666400,
                "headline": "23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs"
              },
              {
                "id": 141259118,
                "url": "https://finnhub.io/api/news?id=a4f03eaf20b67dad07870e03380efd8a674caf30e00758efdf24378602e63067",
                "image": "",
                "source": "Fintel",
                "related": "RMD",
                "summary": "",
                "category": "company",
                "datetime": 1787196494,
                "headline": "Rothschild & Co Initiates Coverage of ResMed (RMD) with Neutral Recommendation"
              },
              {
                "id": 141255098,
                "url": "https://finnhub.io/api/news?id=407cd590acc44067e69ec21c3b5d573dbff31e348a254be4edac3e8cfcac88f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Moderna upgraded, Baidu downgraded: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1787150302,
                "headline": "Moderna upgraded, Baidu downgraded: Wall Street's top analyst calls"
              },
              {
                "id": 141256632,
                "url": "https://finnhub.io/api/news?id=fd6b4b9263365d5e722887f53950c3a77f3efafa38fb8a58e4e469ccdde30b51",
                "image": "",
                "source": "Benzinga",
                "related": "RMD",
                "summary": "Rothschild & Co  analyst Jackson Philips   initiates coverage on ResMed (NYSE:RMD) with a Neutral rating and announces Price Target of $230.",
                "category": "company",
                "datetime": 1787136422,
                "headline": "Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230"
              },
              {
                "id": 141275168,
                "url": "https://finnhub.io/api/news?id=d7b51c821cf9fe215aaaa953f0549364955e01771163a66d11ebe4d793d545dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Nominating and Governance Chair Carol Burt to become Lead Director.Ron Taylor to retire after more than 21 years of service on Resmed’s Board of Directors. SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Carol Burt will become Lead Director on November 15, 2026. She will succeed Ron Taylor, Resmed’s current Lead Director, who is not standing for reelec",
                "category": "company",
                "datetime": 1787001000,
                "headline": "Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor"
              },
              {
                "id": 141275169,
                "url": "https://finnhub.io/api/news?id=7780e3047802952d0dfd4c4557447523f9ac589aafe27fbd60e4ba7e88234d2e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "On August 6, ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 results capping a year of double-digit growth. Quarterly revenue rose 9% to $1.5 billion, and non-GAAP earnings per share jumped 16% to $2.95. For the full fiscal year, which closed June 30, 2026, revenue grew 10%, and free cash flow topped $1.6 billion. The company also […]",
                "category": "company",
                "datetime": 1786998538,
                "headline": "ResMed’s (RMD) Sleep Business Booms Even As One Product Stumbles"
              },
              {
                "id": 141231506,
                "url": "https://finnhub.io/api/news?id=9d892d1c46fc34e76484400133ccfacd3aaf49d29a7d83b06d9eef6c6da6ce1f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1562199023/image_1562199023.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "RMD",
                "summary": "Weekly dividend stock updates: 21 hikes, 1 cut, 1 special. See top picks BR, CSL & RMD—quality, safety and undervaluation.",
                "category": "company",
                "datetime": 1786873045,
                "headline": "Dividend Announcements: August 1-7, 2026"
              },
              {
                "id": 141275170,
                "url": "https://finnhub.io/api/news?id=6371657146a246ced85086464094f9c3f25cc3b7f2e579b5849970dd201bf7f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "ResMed’s second quarter saw steady revenue growth, but the market responded negatively as the company’s operating margin declined year over year. Management attributed the margin compression primarily to higher R&D and supply chain costs amid inflation, despite continued demand for sleep devices and masks. CEO Mick Farrell pointed to ongoing investments in innovation and supply chain efficiency as both a necessity and a source of margin challenges. Additionally, ResMed took a $42 million charge",
                "category": "company",
                "datetime": 1786801020,
                "headline": "The 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call"
              },
              {
                "id": 141220362,
                "url": "https://finnhub.io/api/news?id=aca754d054c2cc29e122e29d60fc10d0d806a9a9424655c9d9e085ef4de25d34",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "RMD",
                "summary": "Weekly dividend summary for Dividend Champions, Contenders & Challengers—read the full list of dividend changes, upcoming ex-dividend dates and pay dates here.",
                "category": "company",
                "datetime": 1786730477,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week August 16"
              },
              {
                "id": 141275171,
                "url": "https://finnhub.io/api/news?id=b5f32ab2e3e87e8f0847e4ace796197049f06e41e2447e0e089e91e61cf5fb74",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Farrell discusses strategic divestitures, capital returns, and AI digital health expansion.",
                "category": "company",
                "datetime": 1786724008,
                "headline": "ResMed (RMD) Q4 2026 Earnings Call Transcript"
              },
              {
                "id": 141192693,
                "url": "https://finnhub.io/api/news?id=1a51c3fda625137f05bd7a8622dd3db9cd4f97aa3ff563d6f1aa5511d9562da4",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "RMD",
                "summary": "As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.",
                "category": "company",
                "datetime": 1786538101,
                "headline": "Which S&P500 stocks are moving before the opening bell on Wednesday?"
              },
              {
                "id": 141202371,
                "url": "https://finnhub.io/api/news?id=a14265c9592c375e48e5eb528b975618d736e006f258f344b092ca3a052a5fc6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "ResMed stock has lagged over the past year, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples currently point to the shares trading at a discount to what the underlying cash flows may justify. ResMed has returned 26.3% over the past 3 years, which suggests that longer term holders have still seen gains despite the recent share price weakness. Recent pressure around a softer outlook and suspended ventilator sales can weigh on sentiment, while...",
                "category": "company",
                "datetime": 1786529545,
                "headline": "ResMed (RMD) Stock May Be 31% Undervalued After Soft FY27 Outlook"
              },
              {
                "id": 141202372,
                "url": "https://finnhub.io/api/news?id=ac834b7859cf4b846702996dda6c6e37f63e3abb547173b38d11e3b8ddae9292",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "In early August 2026, ResMed reported past fourth-quarter and full-year results showing higher sales and earnings, announced a 10% increase in its quarterly US$0.66 dividend, and confirmed completion of a long-running US$1.40 billions share buyback program. At the same time, management issued a softer fiscal 2027 outlook tied to suspended ventilator sales after an FDA Class 1 recall and ongoing cost pressures, sharpening investor focus on how resilient ResMed’s broader sleep-health and...",
                "category": "company",
                "datetime": 1786502030,
                "headline": "Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)?"
              },
              {
                "id": 141202373,
                "url": "https://finnhub.io/api/news?id=7c4506bd336d7052bb2aa2945f9f087fdc744710d9111a84d3688d4b0a575537",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.",
                "category": "company",
                "datetime": 1786465380,
                "headline": "Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists"
              },
              {
                "id": 141202374,
                "url": "https://finnhub.io/api/news?id=c9a55f0c358b934750870cb43810aa47c1355f539cbb188366e6b5733580ef3c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.",
                "category": "company",
                "datetime": 1786465320,
                "headline": "Should Investors Buy Inogen as Low Valuation Meets Execution Risk?"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 6,
            "negative_hits": 0,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.4,
            "source_article_count": 24,
            "discarded_article_count": 18
          },
          "sentimentPoints": 3
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 15.5,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 1,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1,
            "vcp_reason": "跌縮量(近10日5日)；站上MA50；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 2,
              "vol_ref": 1483826.6666666667,
              "down_days": 7,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 1386930,
              "avg_vol_20": 1373910,
              "avg_vol_30": 1483826.6666666667,
              "range_pct_10": 0.11567533472993898,
              "range_pct_20": 0.11567533472993898,
              "range_pct_30": 0.18398756717369524,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9346981228714943,
              "dist_to_20d_high": 0.09414187682103448,
              "down_shrink_days": 5,
              "breakout_level_20d": 242.39999,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.6287127793843513
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 1.6,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 1,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.7764823754440293,
              "turnoverUsdM": 181.39262262,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.RMD",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 207.3868,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2.5,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 5.6,
            "take_profit_price": 232.515,
            "target_multiplier": 1.9,
            "technical_strength": 1.68,
            "take_profit_percent": 5.9
          },
          "positionPoints": 1.4,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.552964750888059,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.RMD",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 6.0966,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.78
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -128.51
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.009
    },
    "kdj": {
      "d": 28.09,
      "j": -4.92,
      "k": 17.08,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 49.02
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 5206711,
      "recentSlope": -879138.9,
      "previousSlope": 62700
    },
    "rsi": 37.14,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 236.0934,
      "position": "SAR喺價上",
      "distancePct": 7.52,
      "previousTrend": "下降"
    },
    "ma50": 216.6216,
    "macd": {
      "macd": 1.9889271258058443,
      "trend": "中性偏多",
      "signal": 4.664611625759994,
      "histogram": -2.6756844999541496
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 229.629,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.61,
      "score": 2,
      "avgVolume": 1345059,
      "currentVolume": 826089
    },
    "derived": {
      "ma20": 229.1715,
      "ma50": 216.6216,
      "prevClose": 219.95,
      "avgVolume10": 1315309,
      "avgVolume20": 1345059,
      "changePercent": -0.17,
      "avgVolumeForScore": 1345059
    },
    "ma_cross": {
      "ma20": 229.1715,
      "ma50": 216.6216,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 229.4925,
      "prevMa50": 216.1276,
      "spreadPct": 5.79,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 216.1695,
      "upper": 242.1735,
      "position": "中間"
    },
    "rsi_short": 0,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.61
    }
  }
}

{
  "close": 219.58,
  "volume": 826089,
  "changePercent": -0.17
}